...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical rheumatology. >The efficacy of continuous versus intermittent celecoxib treatment in osteoarthritis patients aged <60 and ≥60 years
【24h】

The efficacy of continuous versus intermittent celecoxib treatment in osteoarthritis patients aged <60 and ≥60 years

机译：连续性和间歇性塞来昔布治疗<60岁和≥60岁的骨关节炎患者的疗效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To characterize the effect of age on the efficacy of continuous versus intermittent celecoxib treatment. Materials & methods: Prespecified exploratory analysis of a double-blind, parallel-group, randomized, multicenter international study. A total of 858 patients with osteoarthritis of the knee or hip were randomized to receive celecoxib 200 mg/day either as continuous or intermittent treatment. Efficacy was measured by the Western Ontario and McMaster Universities Osteoarthritis Index total and subscale scores, and the number of flare events. Results: Least squares mean increases (worsening) in Western Ontario and McMaster Universities Osteoarthritis Index total scores were significantly less in the continuous than in the intermittent treatment group in patients aged <60 years (1.10 vs 5.32; p = 0.002). In patients aged ≥60 years, the difference between treatment groups was not significant (2.24 vs 4.60; p = 0.111). Fewer flares were reported in the continuous than in the intermittent treatment group in patients aged <60 years (0.50 vs 0.89; p < 0.0001) and ≥60 years (0.59 vs 0.97; p = 0.0001). There were no differences in adverse events in the two age groups. Conclusion: Continuous celecoxib treatment was significantly more efficacious than intermittent use, irrespective of patients age. These data may be useful in considering the treatment of osteoarthritis patients aged ≥60 years.
机译：目的：鉴定年龄对持续性和间歇性塞来昔布治疗疗效的影响。材料和方法：对双盲，平行组，随机，多中心国际研究的预先确定的探索性分析。总共858例膝或髋骨关节炎患者被随机分配接受200毫克/天的塞来昔布连续或间歇治疗。通过西安大略省和麦克马斯特大学骨关节炎指数的总分和分量表得分以及耀斑事件的数量来衡量疗效。结果：西安大略省和麦克马斯特大学骨关节炎指数的最小二乘均值增加（恶化）在60岁以下的患者中，连续治疗组的总得分显着低于间歇治疗组（1.10 vs 5.32; p = 0.002）。在≥60岁的患者中，治疗组之间的差异不显着（2.24 vs 4.60; p = 0.111）。在60岁以下（0.50 vs 0.89; p <0.0001）和≥60岁（0.59 vs 0.97; p = 0.0001）的患者中，连续治疗组比间歇治疗组发生的耀斑较少。在两个年龄段中，不良事件没有差异。结论：塞来昔布连续治疗比间歇使用更有效，而与患者年龄无关。这些数据可能有助于考虑治疗≥60岁的骨关节炎患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号